Sophia Genetics

Sophia Genetics has a fundamental new approach to the credible development and clinical adoption of Data Driven Medicine, pragmatically focused on achieving best patient outcomes while securing patients’ personal genomic data. It’s software as a service (SaaS) offering, dropGen,™ covers the bioinformatic analysis protocol, the validation and quality control process, the presentation of results of genetic tests to clinicians and the protection of patient DNA sequence data through safe storage and banking.

Sophia Genetics has a trio of co-founders who are recognized experts in the field of genetics, bioinformatics and molecular biology and they have built a team of highly qualified PhDs from the top 10 Universities in the world. In just three years, Sophia Genetics has developed bioinformatics pipelines and visualization tools for more than 70 commercial panels, proprietary custom panels and is extending that capability to whole exomes and genomes. The company obtains CE-IVD marking for each supported pipeline and has received ISO 13485 certification.


Recent News

October 19, 2016
Sophia Genetics, spécialisée dans la bio-informatique, vise les Etats-Unis

 
September 13, 2016
Sophia Genetics and Illumina Sign Co-Marketing Agreement to Speed Adoption of Next-Generation Sequencing (NGS) in Clinical Diagnostics

 
November 26, 2015
Sophia Genetics reaches milestone to become the global leader in precision medicine, connecting over 100 hospitals and laboratories to form the world’s largest clinical genomics community for molecular diagnosis

 
October 6, 2014
Sophia Genetics Adds Cystic Fibrosis Analysis to Clinical Bioinformatics Portfolio

 
September 2, 2014
Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing

 
July 8, 2014
Sophia Genetics raises Series B round led by Invoke Capital

 
June 12, 2007
Endeavour Vision announces first closing on Endeavour II, a €160 million European Venture Fund.

 


Company Info
 
Country: Switzerland
Industry:    Medtech
Sector: medical technology
Status: Unrealized
Vehicle: Dedicated vehicle


Key persons
 Jurgi Camblong, CEO


Company website
 www.sophiagenetics.com


Endeavour Vision Team
 
Sven Lingjaerde
Daniel Bertholet
© Endeavour Vision SA 2006-2017 Terms & Conditions